The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients.

摘要: Liver disease due to metabolic dysfunction constitute a worldwide growing health issue. Severe obesity is particularly strong risk factor for non-alcoholic fatty liver disease, which affects up 93% of these patients. Current diagnostic markers focus on the detection advanced fibrosis as major predictor liver-related morbidity and mortality. The most accurate tools use elastography measure stiffness, with accuracies similar in normal-weight severely obese effectiveness are however hampered by limitations equipment measurement quality patients very large abdominal circumference subcutaneous fat. Blood-based biomarkers therefore attractive, but those available date have only moderate accuracy. Ongoing technological advances omics technologies such genomics, transcriptomics, proteomics hold great promise discovery increased pathophysiological understanding steatohepatitis. Very recent developments allowed single-cell sequencing cell-type resolution gene expression function. In near future, we will likely see multitude breakthrough biomarkers, developed from deepened biological function individual cell types healthy injured liver.